Navigation Links
Conatus Pharmaceuticals Acquires Pfizer's Idun Subsidiary
Date:7/30/2010

SAN DIEGO, July 30 /PRNewswire/ -- Conatus Pharmaceuticals Inc. announced today that Conatus acquired the Idun Pharmaceuticals subsidiary of Pfizer Inc.  Financial terms were not disclosed.  Conatus Pharmaceuticals is a privately-held drug development company focused on liver disease and oncology.

Conatus Pharmaceuticals is led by Steven J. Mento, Ph.D., the former CEO of Idun Pharmaceuticals, which was acquired by Pfizer Inc. in 2005.  "The addition of Idun to Conatus continues our important work in liver disease and expands our therapeutic reach into oncology," said Dr. Mento.  "Conatus plans to leverage its scientific and drug development expertise and resources to continue to advance potentially important therapeutic candidates in liver disease and oncology."

Idun Pharmaceuticals was a privately-held biopharmaceutical company engaged in the discovery and development of drug candidates to control apoptosis. At the time of the acquisition by Pfizer, Idun had a Phase 2 drug candidate in liver disease (emricasan/IDN-6556), preclinical drug candidates including IDN-13389 for oncology, a development agreement with Abbott for an oncology drug candidate, and key intellectual property in the field of apoptosis.  Conatus' SVP Corporate Development, Jennifer Giottonini Cayer added, "We appreciate the contributions of Pfizer's colleagues on these potentially important drug candidates.  Conatus is excited to have the opportunity to work on these programs."  

Conatus Pharmaceuticals Inc. is a privately-held pharmaceutical company engaged in the development of innovative human therapeutics to treat liver disease and oncology. The lead drug candidate, CTS-1027 is in multiple Phase 2 clinical trials for the treatment of hepatitis C virus (HCV).  Conatus was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the sale of Idun to Pfizer. For additional information, please visit www.conatuspharma.com.


'/>"/>
SOURCE Conatus Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Conatus Pharmaceuticals Initiates Phase II Clinical Trial in Combination With Pegylated Interferon and Ribavirin for the Treatment of Hepatitis C Virus (HCV)
2. Conatus Pharmaceuticals to Present at the Montgomery Healthcare Conference
3. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
4. Conatus Pharmaceuticals Reports Positive Results of CTS-1027 in Multiple Preclinical Studies of Liver Disease
5. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
6. New FDLI Monograph Provides Expert Guidance on Selling Pharmaceuticals, Biologics to Federal Government
7. Oxford Finance Corporation Leads $30 Million Secured Loan Facility for Cadence Pharmaceuticals
8. Topaz Pharmaceuticals Announces Positive Data from Topical Ivermectin Trials Presented at Society of Pediatric Dermatology
9. Intercept Pharmaceuticals to Collaborate With NIDDK on Study of Obeticholic Acid (INT-747) in Nonalcoholic Steatohepatitis (NASH)
10. HemaQuest Pharmaceuticals Raises Additional $4M to Bring Total to $16M in Series B Financing
11. Amylin Pharmaceuticals to Present at the Wedbush Life Sciences Conference 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Redwood Scientific Technologies, Inc. ... product designed to help women balance their hormones. This ... technology. Jason Cardiff , President and ... able to help the millions of women across the ... effects of imbalanced hormones. Our research and development team ...
(Date:2/5/2016)... Ontario , Feb. 5, 2016  Aralez Pharmaceuticals ... combination of POZEN Inc. ("POZEN") and Tribute Pharmaceuticals Canada Inc. ... POZEN and shareholders of Tribute. The combined company will ... pharmaceutical company with operations in Canada ... the United States . Under the terms of ...
(Date:2/5/2016)... -- Dehaier Medical Systems Ltd. (Nasdaq: DHRM ... markets and sells medical devices and wearable sleep ... and international markets, today announced its corporate and ... Company,s resources to develop its mobile health business, ... more on its major businesses. As of this ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... ... the company's lighter, sleeker next generation LYNX VR Indoor Trainer with multi-rider capability ... in design and manufacturing not only reduce the weight of the unit, they ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being ... Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for ... of Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect of this informative ...
(Date:2/5/2016)... , ... February 05, 2016 , ... Looking for a ... be at the tips of your toes. Foot massage, whether administered by a professional ... comfort and relaxation. The American Board of Multiple Specialties in Podiatry (ABMSP) ...
(Date:2/5/2016)... ... 05, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Tasting Event at the La Gorce Country Club in Miami Beach on March ...
(Date:2/5/2016)... ... 2016 , ... The American public tends to feel uncomfortable about drinking recycled ... municipal or well water. The recent experience with lead contaminated water in Flint, Michigan, ... way toward increasing public acceptance of recycled waste water as drinking water. , ...
Breaking Medicine News(10 mins):